Prolastin c 1,000 MG/20 ML VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FQSW9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,525
Award facts
- Contract value 100% obligated
- $22,524.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,524.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on January 13, 2026, with an ultimate completion date of February 4, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award represents a single delivery order issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V prime contract, valued at $499,999,999 and awarded in November 2025, provides the contractual framework authorizing the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The company's established performance across numerous delivery orders demonstrates its capability to serve as a critical pharmaceutical supplier for military healthcare operations, with the Prolastin C delivery order exemplifying its role in fulfilling specialized pharmaceutical requirements for Department of Defense medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FQSW9?
SPE2DR26FQSW9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FQSW9 worth?
The government has obligated $22,525 on SPE2DR26FQSW9.
Is contract SPE2DR26FQSW9 an order under another contract?
Yes. SPE2DR26FQSW9 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSW9 competed?
The extent of competition for SPE2DR26FQSW9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award